Armoring T Cells with Engineered Fusion Proteins Enhances Therapeutic Efficacy Against Hematologi...

Presented By: Shannon K. Oda, PhD

Speaker Biography: Dr. Shannon Oda received a Ph.D. in Immunology under the mentorship of Dr. Raul Torres at the University of Colorado Anschutz Medical Campus and completed her postdoctoral training with Dr. Philip Greenberg at the Fred Hutchinson Cancer Research Center...

Webinar: Armoring T Cells with Engineered Fusion Proteins Enhances Therapeutic Efficacy Against Hematological and Solid Tumors

Webinar Abstract: Adoptive cell therapy (ACT) is a promising immunotherapy treatment option that uses genetically modified immune cells (T cells) to eliminate tumors. This approach uses the patients’ own immune cells to generate a “living drug” and can avoid the toxic side effects of other common therapies, such as radiation or chemotherapies. However, the tumor microenvironment (TME) can establish several obstacles to protect the tumor from T cells, including delivery of inhibitory and death signals that shut down T cells, usurping metabolic nutrients, and recruiting and/or converting immune cells to inhibitory phenotypes that block the T cell response...

Earn PACE Credits:
1. Make sure you’re a registered member of Labroots (https://www.labroots.com/ms/webinar/a...)
2. Watch the webinar on YouTube or on the Labroots Website (https://www.labroots.com/ms/webinar/a...)
3. Click Here to get your PACE credits (October 05, 2024): (https://www.labroots.com/credit/pace-...)

Labroots on Social:
Facebook:   / labrootsinc  
Twitter:   / labroots  
LinkedIn:   / labroots  
Instagram:   / labrootsinc  
Pinterest:   / labroots  
SnapChat: labroots_inc